Business
Telo Genomics Advances to the Final Stage of Accreditation from The College of American Pathologists
An Important Accreditation Milestone Achieved Towards Full Commercial Availability Toronto, Onta...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Advances to the Final Stage of Accreditation from The College of American PathologistsAn Important Accreditation Milestone Achieved Towards Full Commercial AvailabilityToronto, Ontario--(Newsfile Corp. - November 7, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A), (the \"Company\" or \"Telo\"), a biotech company pioneering the most comprehensive A.I. based genomic medical testing, is excited to announce that the College of American Pathologists (CAP) Accreditation Office has informed the company that its certification application has been successfully completed.The company may now proceed to an external assessment audit, the final step to receiving the highly valued CAP accreditation. The CAP accreditation process is designed to ensure the highest standard of care for all laboratory patients, during which inspectors examine the laboratory's records and quality control of procedures. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.Telo Genomics expects to complete the CAP audit within the first quarter of 2024. The accreditation process conducted by CAP will also include granting Telo the \"Clinical Laboratory Improvement Amendment\" (CLIA) designation. CLIA-designated laboratories are authorized to offer clinical testing in the US, particularly laboratory developed tests (LDTs). This is a crucial step necessary in making the TeloView diagnostic tests widely available for commercial use.Telo's laboratory facility and its TeloView system will qualify as a genomics molecular pathology testing platform within the CAP/CLIA portfolio of testing categories.To reach this final stage of the accreditation process, Telo has worked diligently with the CAP Accreditation Office over the past year. Telo has also conducted rigorous internal gap analysis to address the requirements of the accreditation.\"After a great deal of work, we are thrilled to reach the final stage of the CAP & CLIA accreditation process,\" said Sherif Louis, Telo's President & CTO. \"Along with our recently achieved ISO 15189 clinical laboratory certification we are ready to offer our TeloView tests commercially to the highest level of standards that meet and exceeds the expectation of treating Physicians, Pharma partners and CROs. The CAP/ CLIA...